Skip to main content

Table 2 Univariate analysis of 28- and 90-day mortality of patients with HBV- ACLF

From: Artificial neural network-based models used for predicting 28- and 90-day mortality of patients with hepatitis B-associated acute-on-chronic liver failure

Patient’s Characteristics

Univariate analysis (28-day mortality)

Univariate analysis (90-day mortality)

β

OR (95% CI)

p value

β

OR (95% CI)

P value

Age (yr)

0.037

1.037 (1.022–1.053)

< 0.001

0.039

1.040 (1.026–1.054)

< 0.001

Male %

−0.056

0.946 (0.608–1.472)

0.805

−0.048

0.953 (0.646–1.406)

0.810

Complications

 Hyponatremia (%)

0.573

1.773 (1.259–2.496)

0.001

0.687

1.977 (1.465–2.668)

< 0.001

 Astices (%)

0.515

1.673 (1.132–2.472)

0.010

0.560

1.751 (1.243–2.465)

0.001

 Spontaneous bacterial peritonitis (%)

0.879

2.409 (1.406–4.012)

0.001

0.733

2.080 (1.291–3.353)

0.003

 HE

1.181

5.623 (2.358–10.891)

< 0.001

1.220

2.235 (1.883–4.837)

< 0.001

 Hepatorenal syndrome (%)

1.214

3.368 (2.162–5.248)

< 0.001

1.277

3.585 (2.413–5.326)

< 0.001

Organ failures

 Liver (%)

1.100

3.005 (1.726–5.230)

< 0.001

1.104

3.016 (1.872–4.860)

< 0.001

 Kidney (%)

1.248

3.483 (1.921–6.316)

< 0.001

1.492

4.446 (2.685–7.363)

< 0.001

 Brain (%)

1.987

7.295 (4.400–12.094)

< 0.001

1.955

7.067 (4.394–11.364)

< 0.001

 Coagulation (%)

1.377

3.963 (2.808–5.593)

< 0.001

1.197

3.309 (2.453–4.499)

< 0.001

 Circulatory (%)

3.034

20.775 (4.975–86.754)

< 0.001

3.034

20.775 (4.975–86.754)

< 0.001

 Respiratory (%)

2.457

11.673 (1.599–85.199)

0.015

2.457

11.673 (1.599–85.199)

0.015

Treatment with NUCs (%)

−0.547

0.388 (0.249–0.604)

< 0.001

−0.870

0.419 (0.281–0.625)

< 0.001

 Lamivudine alone (%)

−0.234

0.791 (0.527–1.189)

0.259

−0.127

0.881 (0.624–1.243)

0.470

 Entecavir alone (%)

−0.079

0.924 (0.657–1.300)

0.649

−0.164

0.848 (0.629–1.144)

0.281

 Adefovir alone (%)

−0.159

0.853 (0.349–2.085)

0.727

−0.439

0.644 (0.265–1.569)

0.333

 Telbivudine alone (%)

−3.013

0.049 (0.000–208.362)

0.480

−0.361

0.697 (0.098–4.975)

0719

  ≥ 2 NUCs (%)

−0.329

0.719 (0.366–1.416)

0.340

−0.079

0.924 (0.544–1.569)

0.770

Laboratory data

 ALT (U·L−1)

0.000

1.000 (1.000–1.000)

0.520

0.000

1.000 (1.000–1.000)

0.478

 AST (U·L−1)

0.000

1.000 (1.000–1.000)

0.533

0.000

1.000 (1.000–1.000)

0.900

 TBIL (μmol·L−1)

0.003

1.003 (1.002–1.004)

< 0.001

0.003

1.003 (1.003–1.004)

< 0.001

 Albumin (g·L−1)

−0.028

0.972 (0.938–1.008)

0.124

−0.056

0.946 (0.917–0.976)

0.001

GGT (U·L−1)

−0.004

0.996 (0.993–0.999)

0.006

−0.004

0.997 (0.994–0.999)

0.005

 ALP (U·L−1)

−0.005

0.995 (0.991–0.999)

0.009

−0.003

0.997 (0.993–1.000)

0.034

 Cholinesterase (U·L−1)

0.000

1.000 (1.000–1.000)

0.277

0.000

1.000 (1.000–1.000)

0.008

 PTA (%)

−0.096

0.908 (0.891–0.926)

< 0.001

− 0.081

0.922 (0.907–0.937)

< 0.001

 INR

0.785

2.193 (1.936–2.485)

< 0.001

0.773

2.166 (1.915–2.448)

< 0.001

 White blood cell (×109·L−1)

0.082

1.085 (1.050–1.121)

< 0.001

0.083

1.087 (1.057–1.118)

0.083

 Neutrophil count (×109·L−1)

0.091

1.096 (1.059–1.133)

< 0.001

0.092

1.097 (1.066–1.129)

< 0.001

 Lymphocyte count (× 109·L−1)

− 0.364

0.695 (0.521–0.928)

0.014

−0.288

0.750 (0.587–0.958)

0.021

NLR

0.128

1.136 (1.078–1.198)

< 0.001

–

–

–

 Platelet count (×109·L−1)

−0.002

0.998 (0.995–1.002)

0.371

0.148

1.159 (1.094–1.229)

< 0.001

 Serum potassium (mmol·L−1)

0.361

1.435 (1.140–1.807)

0.002

−0.002

0.998 (0.995–1.001)

0.298

 Serum sodium (mmol·L−1)

−0.080

0.923 (0.892–0.955)

< 0.001

0.321

1.379 (1.113–1.708)

0.003

 Serum creatinine (mg·dL−1)

0.005

1.005(1.003–1.006)

< 0.001

−0.096

0.909 (0.882–0.937)

< 0.001

 HBeAg positive rate

−0.485

0.616(0.429–0.884)

0.009

0.005

1.005 (1.003–1.006)

< 0.001

 HBV-DNA level (Log10copies·mL−1)

0.031

1.032 (0.918–1.160)

0.602

−0.485

0.616 (0.448–0.847)

0.003

  1. OR odds ratio, 95% CI 95% confidence interval, HBV hepatitis B virus, ACLF acute-on chronic liver failure, NUCs nucleotide analogs, HE hepatic encephalopathy, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase, PTA prothrombin activity, INR international normalized ratio, MELD model of end-stage liver disease, MELD-Na MELD integrating sodium, HBeAg hepatitis B e antigen
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us